Up to 88% of patients in the treatment group had at least a 10% weight loss, if not more, compared with 4% for placebo
Some researchers keep a 5mg vial specifically for the first two weeks at 1mg (using just 20 units per dose), then switch to larger vials for the remainder of the protocol
These often improve as the body adjusts
Among GLP-1 RA users in the final study sample, the proportion of semaglutide users increased from 5.1% in 2018 to 63% in 2023 ( Meanwhile, from 2018 to 2023, the proportion of diabetic GLP-1 RA users decreased from 89% to 66%, respectively, and those without a diagnosis of diabetes (groups 3 and 4) tripled their share from 11% to 34% ( Among group 3 (without diabetes and without obesity/overweight), there was a steady increase in off-label semaglutide (Ozempic) prescribing from 3.6% to 30%, and off-label semaglutide (Wegovy) increased to 38% drug share in 2023
Limnology and Oceanography 56 : 13301342.CrossRefGoogle Scholar Helbling, E